Patient characteristics
| Patient SPN . | Age, y . | Sex . | Disease . | Prior treatment . | Type of preparative regimen . | Preparative regimen . | Graft composition . | GVHD . | Status at d + 180 . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TNC (× 109) . | CD34+/kg (× 106) . | CD3+/kg (× 108) . | |||||||||
| 2240 | 45 | F | CML | HU | Myeloablative | Bu/Cy | 22 | NA | NA | 0 | Cytog rel |
| 2242 | 27 | F | AML | Ida-Ara/Ara | Myeloablative | FTBI/Etop | 177 | 23 | 3 | 0 | Alive/CR |
| 2246 | 52 | F | NHL | CHOP/ESHAP | Myeloablative | BCNU/Etop/Cy | 88 | 9 | 3 | 0 | Alive/CR |
| 2250 | 31 | M | CML-BP | HU/IFN/VINC/Pred | Myeloablative | FTBI/Etop/Cy | 145 | 15 | 3 | SkinAc2 | Alive/CR |
| 2252 | 43 | F | CML | HU/IFN | Myeloablative | Bu/Cy | 24 | NA | NA | Mouth Ch | Alive/CR |
| 2443 | 33 | M | CML | HU | Myeloablative | Bu/Cy | 32 | 2 | 0.4 | 0 | NA |
| 2444 | 46 | M | AML | Ida-Ara/Ara | Myeloablative | FTBI/Etop | 291 | 9 | 3 | 0 | NA |
| 2446 | 28 | F | AML | Ida-Ara/Ara | Myeloablative | FTBI/Etop | 95 | 6 | 2 | 0 | NA |
| 2185 | 61 | M | MM | XRT/VAD/Thal/AutoTX | Nonmyeloablative | Flu/TBI | 47 | 6 | 2 | Mouth Ch | Alive/PR |
| 2270 | 62 | M | MM | VAD/AutoTX | Nonmyeloablative | Flu/TBI | 176 | 8 | 4 | 0 | Alive/PR |
| 2320 | 52 | M | CLL | Flu/CVPB/Campath | Nonmyeloablative | Flu/TBI | 134 | 5 | 3 | 0 | Alive/PR |
| 2331 | 62 | F | MDS | None | Nonmyeloablative | Flu/TBI | 67 | 8 | 3 | GiAc2 | Alive/CR |
| 2238 | 58 | M | MM | VAD/Cy/AutoTX | Nonmyeloablative | Flu/TBI | 125 | 12 | 2 | 0 | Alive/PR |
| 2251 | 61 | F | MM | MP/VAD/AutoTX | Nonmyeloablative | Flu/TBI | 179 | 10 | 4 | 0 | Died sepsis |
| 2307 | 71 | M | MM | MP/XRT/AutoTX | Nonmyeloablative | Flu/TBI | 147 | 2 | 5 | 0 | Alive/PR |
| 2337 | 64 | M | MM | VAD/XRT/AutoTX | Nonmyeloablative | Flu/TBI | 156 | 7 | 4 | 0 | Alive/PR |
| 2410 | 61 | M | MF | None | Nonmyeloablative | Flu/TBI | 106 | 7 | 4 | 0 | NA |
| 2452 | 60 | F | MM | VAD/AutoTX | Nonmyeloablative | Flu/TBI | 135 | 12 | 7 | 0 | NA |
| 2492 | 61 | M | NHL | CHOP, Flu/Cy/rituxmab | Nonmyeloablative | Flu/TBI | 120 | 13 | 4 | 0 | NA |
| Patient SPN . | Age, y . | Sex . | Disease . | Prior treatment . | Type of preparative regimen . | Preparative regimen . | Graft composition . | GVHD . | Status at d + 180 . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TNC (× 109) . | CD34+/kg (× 106) . | CD3+/kg (× 108) . | |||||||||
| 2240 | 45 | F | CML | HU | Myeloablative | Bu/Cy | 22 | NA | NA | 0 | Cytog rel |
| 2242 | 27 | F | AML | Ida-Ara/Ara | Myeloablative | FTBI/Etop | 177 | 23 | 3 | 0 | Alive/CR |
| 2246 | 52 | F | NHL | CHOP/ESHAP | Myeloablative | BCNU/Etop/Cy | 88 | 9 | 3 | 0 | Alive/CR |
| 2250 | 31 | M | CML-BP | HU/IFN/VINC/Pred | Myeloablative | FTBI/Etop/Cy | 145 | 15 | 3 | SkinAc2 | Alive/CR |
| 2252 | 43 | F | CML | HU/IFN | Myeloablative | Bu/Cy | 24 | NA | NA | Mouth Ch | Alive/CR |
| 2443 | 33 | M | CML | HU | Myeloablative | Bu/Cy | 32 | 2 | 0.4 | 0 | NA |
| 2444 | 46 | M | AML | Ida-Ara/Ara | Myeloablative | FTBI/Etop | 291 | 9 | 3 | 0 | NA |
| 2446 | 28 | F | AML | Ida-Ara/Ara | Myeloablative | FTBI/Etop | 95 | 6 | 2 | 0 | NA |
| 2185 | 61 | M | MM | XRT/VAD/Thal/AutoTX | Nonmyeloablative | Flu/TBI | 47 | 6 | 2 | Mouth Ch | Alive/PR |
| 2270 | 62 | M | MM | VAD/AutoTX | Nonmyeloablative | Flu/TBI | 176 | 8 | 4 | 0 | Alive/PR |
| 2320 | 52 | M | CLL | Flu/CVPB/Campath | Nonmyeloablative | Flu/TBI | 134 | 5 | 3 | 0 | Alive/PR |
| 2331 | 62 | F | MDS | None | Nonmyeloablative | Flu/TBI | 67 | 8 | 3 | GiAc2 | Alive/CR |
| 2238 | 58 | M | MM | VAD/Cy/AutoTX | Nonmyeloablative | Flu/TBI | 125 | 12 | 2 | 0 | Alive/PR |
| 2251 | 61 | F | MM | MP/VAD/AutoTX | Nonmyeloablative | Flu/TBI | 179 | 10 | 4 | 0 | Died sepsis |
| 2307 | 71 | M | MM | MP/XRT/AutoTX | Nonmyeloablative | Flu/TBI | 147 | 2 | 5 | 0 | Alive/PR |
| 2337 | 64 | M | MM | VAD/XRT/AutoTX | Nonmyeloablative | Flu/TBI | 156 | 7 | 4 | 0 | Alive/PR |
| 2410 | 61 | M | MF | None | Nonmyeloablative | Flu/TBI | 106 | 7 | 4 | 0 | NA |
| 2452 | 60 | F | MM | VAD/AutoTX | Nonmyeloablative | Flu/TBI | 135 | 12 | 7 | 0 | NA |
| 2492 | 61 | M | NHL | CHOP, Flu/Cy/rituxmab | Nonmyeloablative | Flu/TBI | 120 | 13 | 4 | 0 | NA |
SPN indicates Stanford patient number; TNC, total nucleated cells; GVHD, graft-versus-host disease; CML, chronic myeloid leukemia; BP, blast phase; HU, hydroxyurea; Bu, busulfan; Cy, cyclophosphamide; Vinc, vincristine; Pred, prednisone; NA, not available; Cytog rel, cytogenetic relapse; AML, acute myeloid leukemia; Ida, idarubicin; Ara, cytarabinoside; FTBI, fractionated total body irradiation; Etop, etoposide; CR, complete remission; NHL, non-Hodgkin lymphoma; CHOP, cyclophosphamide, adriamycin, vincristine, and prednisone; ESHAP, etoposide, cytarabinoside, prednisone, and cisplatinum; BCNU, carmustine; Flu, fludarabine; IFN, interferon; Mouth Ch, chronic GVHD of the oral cavity; MM, multiple myeloma; XRT, radiotherapy; VAD, vincristine, Adriamycin, and dexamethasone; Thal, thalidomide; AutoTX, high-dose chemotherapy with autologous hematopoietic rescue; TBI, total body irradiation; PR, partial remission; CLL, chronic lymphatic leukemia; CVBP, cyclophosphamide, vincristine, bleomycin, and prednisone; Campath, antibody against CD52; MDS, myelodysplastic syndrome; GiAc2, acute GVHD grade 2 of the gastrointestinal system; MP, melphalan, prednisone; MF, myelofibrosis; and rituximab, antibody against CD20.